Impact of antibiotic resistance and of adequate empirical antibiotic treatment in the prognosis of patients with Escherichia coli bacteraemia

Journal of Antimicrobial Chemotherapy

Volumn 60, Issue 4, 2007, Pages 855-863

  Peralta, Galo ^a   SanchezM B M Blanca ^b   Garrido, J Carlos ^a   De Benito, Inés ^a   Cano, M Eliecer ^b   Martínez Martínez, Luis ^b,c   Roiz, M Pía ^a  

^a HOSPITAL SIERRALLANA   (Spain)

^b HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^c UNIVERSITY OF CANTABRIA   (Spain)

Author keywords

Antimicrobial susceptibility; Antimicrobial treatments; Bloodstream infections; Gram negative bacteria; Inadequate therapy; Mortality

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; ANTIBIOTIC AGENT; CEFEPIME; CEFOTAXIME; CEFTRIAXONE; CEFUROXIME; CIPROFLOXACIN; COTRIMOXAZOLE; FOSFOMYCIN; GENTAMICIN; IMIPENEM; LEVOFLOXACIN; MEROPENEM; NORFLOXACIN; PIPEMIDIC ACID; PIPERACILLIN PLUS TAZOBACTAM;

ADULT; AGE; AGED; ALPHA HEMOLYTIC STREPTOCOCCUS; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTEREMIA; BACTERIUM ISOLATION; BACTEROIDES; BLOOD CULTURE; COHORT ANALYSIS; CONTROLLED STUDY; DEATH; DISEASE SEVERITY; ENTEROCOCCUS FAECALIS; ESCHERICHIA COLI; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIDRUG RESISTANCE; MULTIVARIATE ANALYSIS; OUTCOME ASSESSMENT; PROGNOSIS; RISK ASSESSMENT; RISK FACTOR; SCORING SYSTEM; SEPSIS; SHOCK; SPAIN; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BACTEREMIA; COHORT STUDIES; DRUG RESISTANCE, BACTERIAL; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; RETROSPECTIVE STUDIES; RISK FACTORS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 34548728516     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkm279     Document Type: Article

References (43)

1. Javaloyas MD, Garcia-Somoza D, Gudiol F. Epidemiology and prognosis of bacteremia: A 10 year study in a community hospital. Scand J infect Dis 2002; 34: 436-41.
2. Weinstein MP, Towns ML, Quartey S et al. The clinical significance of positive blood culture in the 1990s: A prospective comprehensive evaluation of the microbiology, epidemiology, and outcome of bacteremia and fungemia in adults. Clin Infect Dis 1997; 24: 584-602.
3. Gransden WR, Eykyn SJ, Phillips I et al. Bacteremia due to Escherichia coli: A study of 861 episodes. Rev Infect Dis 1990; 12: 1008-18.
4. Olesen B, Kolmos FU, Orskov F et al. Bacteraemia due to Escherichia coli in a Danish university hospital, 1986-1990. Scand J Infect Dis 1995; 27: 253-7.
5. Javaloyas M, Garcia-Somoza D, Gudiol F. Bacteremia due to Escherichia coli: Epidemiological analysis and sensitivity to antibiotics in a county hospital. Med Clin (Barc) 2003; 120: 125-7.
6. Vazquez F, Mendoza MC, Viejo G et al. Survey of Escherichia coli septicemia over a six-year period. Eur J Clin Microbiol Infect Dis 1992; 11: 110-7.
7. Kuikka A, Sivonen A, Emelianova A et al. Prognostic factors associated with improved outcome of Escherichia coli bacteremia in a Finnish university hospital. Eur J Clin Microbiol Infect Dis 1997; 16: 125-34.
8. Martinez JA, Sato S, Fabrega A et al. Relationship of phylogenetic background, biofilm production, and time to detection of growth in blood culture vials with clinical variables and prognosis associated with Escherichia coli bacteremia. J Clin Microbiol 2006; 44: 1468-74.
9. Bisson G, Fishman NO, Patel JB et al. Extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella species: Risk factors for colonization and impact of antimicrobial formulary interventions on colonization prevalence. Infect Control Hosp Epidemiol 2002; 23: 254-60.
10. D'Agata E, Venkataraman L, DeGirolami P et al. The molecular and clinical epidemiology of Enterobacteriaceae producing extended-spectrum β-lactamase in a tertiary care hospital. J Infect 1998; 36: 279-85.
11. Rodriguez-Baño J, Navarro MD, Romero L et al. Clinical and molecular epidemiology of extended-spectrum β-lactamase-producing Escherichia coli as a cause of nosocomial infection or colonization: implications for control. Clin Infect Dis 2006; 42: 37-45.
12. Paterson DL, Ko WC, Von Gottherg A et al. International prospective study of Klebsiella pneumoniae bacteremia: implications of extended-spectrum β-lactamase production in nosocomial infections. Ann Intern Med 2004; 140: 26-32.
13. Du B, Long Y, Liu H et al. Extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae bloodstream infection: Risk factors and clinical outcome. Intensive Care Med 2002; 28: 1718-23.
14. Schiappa DA, Hayden MK, Matushek MG et al. Ceftazidime-resistant Klebsiella pneumoniae and Escherichia coli bloodstream infection: A case-control and molecular epidemiologic investigation. J Infect Dis 1996; 174: 529-36.
15. Emery CL, Weymouth LA. Detection and clinical significance of extended-spectrum β-lactamases in a tertiary-care medical center. J Clin Microbiol 1997; 35: 2061-7.
16. Kang CI, Kim SH, Park WB et al. Bloodstream infections caused by antibiotic-resistant Gram-negative bacilli: Risk factors for mortality and impact of inappropriate initial antimicrobial therapy on outcome. Antimicrob Agents Chemother 2005; 49: 760-6.
17. Lautenbach E, Strom BL, Bilker WB et al. Epidemiological investigation of fluoroquinolone resistance in infections due to extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae. Clin Infect Dis 2001; 33: 1288-94.
18. Kollet MH. Inadequate antimicrobial treatment: An important determinant of outcome for hospitalized patients. Clin Infect Dis 2000; 31 Suppl 4: S131-8.
19. Ramphal R. Importance of adequate initial antimicrobial therapy. Chemotherapy 2005; 51: 171-6.
20. Charlson ME, Pompei P, Ales KL et al.. A new method of classifying prognostic comorbidity in longitudinal populations: Development and validation. J Chronic Dis 1987; 40: 373-8.
21. Bone RC, Sprung CL, Sibbald WJ. Definitions for sepsis and organ failure. Crit Care Med 1992; 20: 724-6.
22. Bradford PA. Extended-spectrum β-lactamases in the 21st century: characterization, epidemiology and detection of this important resistance threat. Clin Microbiol Rev 2001; 14: 933-51.
23. Rodriguez-Baño J, Navarro MD, Romero L et al. Epidemiology and clinical features of infections used by extended-spectrum β-lactamase-producing Escherichia coli in nonhospitalized patients. J Clin Microbiol 2004; 42: 1089-94.
24. Hernandez JR, Martinez-Martinez L, Canton R et al. Nationwide study of Escherichia coli and Klebsiella pneumoniae producing extended-spectrum β-lactamases in Spain. Antimicrob Agents Chemother 2005; 49: 2122-9.
25. National Committee for Clinical Laboratory Standards. Performance Standards for Antimicrobial Susceptibility Testing: Twelfth Informational Supplement M100-S12. NCCLS, Villanova, PA, USA, 2002.
26. Garau J, Xercavins M, Rodriguez-Carballeira M et al. Emergence and dissemination of quinolone-resistant Escherichia coli in the community. Antimicrob Agents Chemother 1999; 43: 2736-41.
27. Karlowsky JA, Kelly LJ, Thomsberry C et al. Trends in antimicrobial resistance among urinary tract infection isolates of Escherichia coli from female outpatients in the United States. Antimicrob Agents Chemother 2002; 46: 2540-5.
28. Manges AR, Johnson JR, Foxman B et al. Widespread distribution of urinary tract infections caused by a multidrug-resistant Escherichia coli clonal group. N Engl J Med 2001; 345: 1007-13.
29. Sahm DF, Thomsberry C, Mayfield DC et al. Multidrug-resistant urinary tract isolates of Escherichia coli: Prevalence and patient demographics in the United States in 2000. Antimicrob Agents Chemother 2001; 45: 1402-6.
30. Ibrahim EH, Sherman G, Ward S et al. The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. Chest 2000; 118: 146-55.
31. Khatib R, Saeed S, Sharma M et al. Impact of initial antibiotic choice and delayed appropriate treatment on the outcome of Staphylococcus aureus bacteremia. Eur J Clin Microbiol Infect Dis 2006; 25: 181-5.
32. Lujan M, Gallego, M, Fontanals D et al. Prospective observational study of bacteremic pneumococcal pneumonia: Effect of discordant therapy on mortality. Crit Care Med 2004; 32: 625-31.
33. Vergis EN, Hayden MK, Chow JW et al. Determinants of vancomycin resistance and mortality rates in enterococcal bacteremia. A prospective multicenter study. Ann Intern Med 2001; 135: 484-92.
34. Kang CI, Kim SH, Kim HB et al. Pseudomonas aeruginosa bacteremia: risk factors for mortality and influence of delayed receipt of effective antimicrobial therapy on clinical outcome. Clin Infect Dis 2003; 37: 745-51.
35. Falagas ME, Kasiakou SK, Rafailidis PI et al. Comparison of mortality of patients with Acinetobacter baumannii bacteraemia receiving appropriate and inappropriate empirical therapy. J Antimicrob Chemother 2006; 57: 1251-4.
36. Morrell M, Fraser VJ, Kollef MH. Delaying the empiric treatment of Candida bloodstream infection until positive blood culture results are obtained: A potential risk factor for hospital mortality. Antimicrob Agents Chemother 2005; 49: 3640-5.
37. Kang CI, Kim SH, Park WB et al. Bloodstream infections due to extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae: Risk factors for mortality and treatment outcome, with special emphasis on antimicrobial therapy. Antimicrob Agents Chemother 2004; 48: 4574-81.
38. Marra AR, Wey SB, Castelo A et al. Nosocomial bloodstream infections caused by Klebsiella pneumoniae: Impact of extended-spectrum β-lactamase (ESBL) production on clinical outcome in a hospital with high ESBL prevalence. BMC Infect Dis 2006; 6 24.
39. Kang CI, Kim SH, Kim DM et al. Risk factors for and clinical outcomes of bloodstream infections caused by extended-spectrum β-lactamase-producing Klebsiella pneumoniae. Infect Control Hosp Epidemiol 2004; 25: 860-7.
40. Bhavnani SM, Ambrose PG, Craig WA et al. Outcomes evaluation of patients with ESBL- and non-ESBL-producing Escherichia coli and Klebsiella species as defined by CLSI reference methods: Report from the SENTRY Antimicrobial Surveillance Program. Diagn Microbiol Infect Dis 2006; 54: 231-6.
41. Hyle EP, Lipworth AD, Zaoutis TE et al. Impact of inadequate initial antimicrobial therapy on mortality in infections due to extended-spectrum β-lactamase-producing Enterobacteriaceae: variability by site of infection. Arch Intern Med 2005; 165: 1375-80.
42. Lautenbach E, Metlay JP, Biker WB et al. Association between fluoroquinolone resistance and mortality in Escherichia coli and Klebsiella pneumoniae infections: The role of inadequate empirical anti-microbial therapy. Clin Infect Dis 2005; 41: 923-9.
43. Valles J, Rello J, Ochagavia A et al. Community-acquired blood-stream infection in critically ill adult patients: Impact of shock and inappropriate antibiotic therapy on survival. Chest 2003; 123: 1615-24.